klinischen Studien - Klinikum der Universität München

Aktuelle klinische Studien in der Dermato-Onkologie - Hautklinik LMU München
Frauenlobstr. 9-11, 80337 München; Hauptprüfer: Prof. Carola Berking
Malignes Melanom
Indikation: malignes Melanom, Stadium IV postoperativ
Adjuvante Studie, Phase II
Studientitel: A Phase II Randomized, Double-Blind Trial of Immunotherapy with
Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a PostSurgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of
Disease
Studiencode: IMMUNED
EudraCT-Nr.: 2014-001167-12
Sponsor: Universitätsklinikum Essen
Indikation: malignes Melanom, inoperabel Stadium III oder IV, BRAF Mutation
Phase II
Studientitel: A phase II, multi-center, open-label study of sequential LGX818/MEK162
combination followed by a rational combination with targeted agents after
progression, to overcome resistance in adult patients with locally advanced or
metastatic BRAF V600 melanoma
Studiencode: CLGX818X2109, The LOGIC 2 trial
EudraCT-Nr.: 2013-004552-38
Sponsor: Novartis
Indikation: malignes Melanom, Stadium IV, BRAF Wildtyp
Phase II
Studientitel: A Phase I/II, multicenter, randomized, double-blind, placebo-controlled
trial evaluating the efficacy and safety of Nintedanib/Vargatef in combination with
Paclitaxel chemotherapy for treatment of patients with BRAF wildtype metastatic
melanoma - NIPAWILMA EudraCT-Nr. 2013-004458-34
Sponsor: Universitätsklinikum Essen
Indikation: malignes Melanom, inoperabel Stadium III und IV, NRAS Mutation
Phase II
Studientitel: Phase Ib/II, multicenter, open label, study of LEE011 in combination with
MEK 162 in adult patients with NRAS mutant melanoma
Studiencode: CMEK162X2114
EudraCT-Nr.: 2012-004104-35
Sponsor: Novartis
1
Aktuelle klinische Studien in der Dermato-Onkologie - Hautklinik LMU München
Frauenlobstr. 9-11, 80337 München; Hauptprüfer: Prof. Carola Berking
Indikation: malignes Melanom, metastasiert, Erstlinie
Phase IIIb/IV
Studientitel: Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in
Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with
Ipilimumab 3 mg/kg in Subjects with Previously Untreated, Unresectable or
Metastatic Melanoma
Studiencode: CA209-511, CheckMate 511
Sponsor: BMS
Indikation: malignes Melanom, metastasiert, BRAF V600-Mutation
Phase II
Studientitel: A phase II, multicenter, open-label, randomized-controlled trial
evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus
vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab
for the treatment in patients with unresectable or metastatic BRAF V600 mutant
melanoma
Studiencode: ImmunoCobiVem
EudraCT-Nr.: 2015-005097-37
Sponsor: Universitätsklinikum Essen
Indikation: malignes Melanom, Stadium III und IV
Phase III
Studientitel: A Phase 1b/3, Multicenter, Open-label Trial of Talimogene
Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of
Unresected, Stage IIIB to IVM1c Melanoma
Studiencode: MASTERKEY-265; 20110265
EudraCT-Nr.: 2014-000185-22
Sponsor: Amgen
Indikation: malignes Melanom, metastasiert, BRAF V600-Mutation
Phase III
Studientitel: A phase III, double-blinded, randomized, placebo-controlled study of
atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and
vemurafenib in previously untreated BRAF V600 mutation-positive patients with
unresectable locally advanced or metastatic melanoma
Studiencode: Trilogy; CO39262
EudraCT-Nr.: 2016-002482-54
Sponsor: Roche
2
Aktuelle klinische Studien in der Dermato-Onkologie - Hautklinik LMU München
Frauenlobstr. 9-11, 80337 München; Hauptprüfer: Prof. Carola Berking
Plattenepithelkarzinom
Indikation: Plattenepithelkarzinom der Haut, lokal fortgeschritten oder metastasiert
Phase II
Studientitel: A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to
Programmed Death-1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell
Carcinoma (CSCC)
Studiencode: R2810-ONC-1540
Sponsor: Regeneron
Merkelzellkarzinom
Indikation: Merkelzellkarzinom, operiert
Adjuvante Studie
Studientitel: Prospective randomized trial of an adjuvant therapy of completely
resected Merkel Cell Carcinoma (MCC) with 3mg/kg BW Ipilimumab (Yervoy®) every
3 weeks for 12 weeks versus observation
Studiencode: CA184-205
EudraCT-Nr.: 2013-000043-78
Sponsor: Universitätsklinikum Essen
3

Download Report